Target intelligence / Profile preview

Novel transcript, antisense to MIER2 (ENSG00000267124)

Target
ENSG00000267124
Molecular classification
Other (Non-coding RNA, Natural antisense transcript)
01

Overview

This entry represents a natural antisense transcript (NAT) to the MIER2 gene. NATs are endogenous RNA molecules transcribed from the opposite strand of protein-coding genes, and can regulate gene expression of their sense counterpart at multiple levels, including transcription, splicing, RNA stability, transport, and translation[3][4]. The specific transcript "novel transcript, antisense to MIER2" appears to be cataloged based on its sequence but lacks detailed functional characterization and direct links to disease, drug interactions, or classical therapeutic targeting[1]. NATs in general are implicated in fine-tuning gene expression and may participate in cellular regulatory networks, but individual NATs are rarely considered primary therapeutic targets unless well-validated[3][4].

Other names
Novel transcript, antisense to MIER2ENSG00000267124
02

Mechanism of action

Not applicable, as it is not a druggable protein or receptor. Mechanistically, natural antisense transcripts can regulate gene expression mainly by: - RNA masking: Sense-antisense RNA duplex formation blocking protein or miRNA interactions - Transcriptional interference: Disruption of transcription of the sense gene - Epigenetic regulation: Recruiting chromatin modifiers to change gene accessibility

03

Biological functions

Regulation of gene expression via antisense transcription, including possible effects on RNA stability, splicing, and epigenetic modificationPost-transcriptional gene regulation, potentially by masking the sense transcript or forming regulatory RNA duplexes
04

Disease associations

Other (Regulatory non-coding RNAs are being studied in many diseases; however, there is no direct disease association for this specific antisense transcript currently known)
05

Safety considerations

None directly related. As a non-coding RNA, it is not a therapeutic target with drug safety concerns. Theoretical concerns about off-target effects would apply only if manipulated experimentally
06

Interacting drugs

None. There are no known drugs interacting with this non-coding RNA transcript
07

Biomarkers

None associated with this transcript. Natural antisense RNAs are not used as clinical biomarkers for patient selection or efficacy monitoring unless specifically validated in disease contexts, which does not apply here

Beyond the preview

Go deeper on Novel transcript, antisense to MIER2 (ENSG00000267124).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel transcript, antisense to MIER2 (ENSG00000267124).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call